The State issued guidelines for the development of the pharmaceutical industry during the "Eleventh Five-Year Plan" period
Phthalic anhydride appears as a colorless to white lustrous solid in the form of needles with a mild distinctive odor. Moderately toxic by inhalation or ingestion and a skin irritant. Melting point 64°F Flash point 305°F. Forms a corrosive solution when mixed with water. Used in the manufacture of materials such as artificial resins.
Phthalic anhydride is the cyclic dicarboxylic anhydride that is the anhydride of phthalic acid. It has a role as an allergen. It is a cyclic dicarboxylic anhydride and a member of 2-benzofurans.
Phthalic anhydride is one of the most important organic chemical raw materials. Its main derivatives are dibutyl phthalate, dioctyl phthalate and diisobutyl acrylate. It is used as a plasticizer for PVC; it can also be used to produce unsaturated poly Ester resin, alkyd resin, dyes and pigments, various paints, food additives, laxatives in medicine, phenolphthalein, imipenem in pesticides, bentazone and sodium saccharin. Used as an analytical reagent and also for organic synthesis.
Storage Condition:
Phthalic Anhydride,Phthalic Anhydrid,99.5% Phthalic Anhydride,Plasticizer Mf C8H4O3 SHANDONG S-SAILING CHEMICAL CO,LTD , https://www.sdqh-chem.com
The “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†put forward the main development goals of the Chinese pharmaceutical industry from 2006 to 2010:
——In the field of chemical raw material medicine, realize the industrialization of 20 products with high market growth potential and high added value;
- In the field of chemical drug preparations, strive to obtain the listing qualification of 5 pharmaceutical products in the United States or EU countries;
——In the field of traditional Chinese medicine products, develop and market 20 to 30 modern Chinese medicine products with perfect quality standards, clear mechanism of efficacy, safety, efficiency, stability, and controllability;
- In the areas of major, acute infectious diseases and chronic severe diseases, strive to achieve the industrialization of 10 to 15 innovative drugs and new vaccines with Chinese independent intellectual property rights;
——In the field of medical device products, 10 to 20 new types of digital, non-invasive or minimally invasive diagnostic and therapeutic equipment and medical materials have been industrialized.
“In the future, China will pay more attention to improving the independent innovation capability of pharmaceutical companies and strengthening the research and development of innovative drugs. According to Zhang Guobao, the current lack of investment in R&D by Chinese pharmaceutical companies and their weak innovation capacity have become the key to the in-depth development of this industry. problem.
According to the “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†and during the “Eleventh Five-Year Plan†period, the R&D investment of Chinese medical devices and key pharmaceutical companies will account for more than 5% of the sales revenue. The R&D investment of pharmaceutical industry companies will reach sales revenue. 3%; Innovative drug research and development will focus on anti-tumor, cardiovascular and cerebrovascular systems, anti-viral infection, neuropsychiatric system, hypoglycemic, geriatric diseases and other fields.
In addition, in the next five years, the country will also cultivate five large-scale pharmaceutical groups with sales of over 5 billion yuan, 10 pharmaceutical commercial enterprises with sales of more than 3 billion yuan, and strive for the initial development of five or so local companies. International pharmaceutical companies.
Zhang Guobao said that the guidance is not mandatory. The purpose of formulating this guidance is mainly to release information and provide suggestions for pharmaceutical companies, guide the healthy and orderly development of the pharmaceutical industry, and promote economic and social progress.
2.Used in the paint industry;
3.Insulation paint and glass fiber reinforced plastics;
4.Drugs.